Preventative Strategies on Meningococcal Disease

Overview

Journal Arch Dis Child

Specialty Pediatrics

Date 1997 Mar 1

PMID 9135255

Authors

R T Mayon-White

P T Heath

Affiliations

Soon will be listed here.

References

Riordan F, Thomson A, Sills J, Hart C . Who spots the spots? Diagnosis and treatment of early meningococcal disease in children. BMJ. 1996; 313(7067):1255-6. PMC: 2352534. DOI: 10.1136/bmj.313.7067.1255. View

Goodman R, Yude C . IQ and its predictors in childhood hemiplegia. Dev Med Child Neurol. 1996; 38(10):881-90. DOI: 10.1111/j.1469-8749.1996.tb15045.x. View

DE MORAES J, Perkins B, Camargo M, Hidalgo N, Barbosa H, Sacchi C . Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992; 340(8827):1074-8. DOI: 10.1016/0140-6736(92)93086-3. View

Jones D, Mallard R . Age incidence of meningococcal infection England and Wales, 1984-1991. J Infect. 1993; 27(1):83-8. DOI: 10.1016/0163-4453(93)93978-d. View

Thomson A, Hayhurst G . Press publicity in meningococcal disease. Arch Dis Child. 1993; 69(1):166-9. PMC: 1029440. DOI: 10.1136/adc.69.1.166. View

Jackson L, Schuchat A, Reeves M, Wenger J . Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA. 1995; 273(5):383-9. View

Twumasi Jr P, Kumah S, Leach A, ODempsey T, Ceesay S, Todd J . A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis. 1995; 171(3):632-8. DOI: 10.1093/infdis/171.3.632. View

Pearce M, SHERIDAN J, Jones D, Lawrence G, Murphy D, Masutti B . Control of group C meningococcal disease in Australian aboriginal children by mass rifampicin chemoprophylaxis and vaccination. Lancet. 1995; 346(8966):20-3. DOI: 10.1016/s0140-6736(95)92651-8. View

Jones D, Kaczmarski E . Meningococcal infections in England and Wales: 1994. Commun Dis Rep CDR Rev. 1995; 5(9):R125-30. View

10.

Herbert M, Heath P, Mayon-White R . Meningococcal vaccines for the United Kingdom. Commun Dis Rep CDR Rev. 1995; 5(9):R130-5. View

11.

Cunliffe N, Snowden N, Dunbar E, Haeney M . Recurrent meningococcal septicaemia and properdin deficiency. J Infect. 1995; 31(1):67-8. DOI: 10.1016/s0163-4453(95)91550-8. View

12.

Kaczmarski E, Cartwright K . Control of meningococcal disease: guidance for microbiologists: CCDC. Consultant in Communicable Disease Control, England. Commun Dis Rep CDR Rev. 1995; 5(13):R196-8. View

13.

Cartwright K, Hunt D, Fox A . Chemoprophylaxis fails to prevent a second case of meningococcal disease in a day nursery. Commun Dis Rep CDR Rev. 1995; 5(13):R199. View

14.

Kristiansen B, Knapskog A . Secondary prevention of meningococcal disease. BMJ. 1996; 312(7031):591-2. PMC: 2350377. DOI: 10.1136/bmj.312.7031.591. View

15.

Goodman R, Yude C . Do incomplete ascertainment and recruitment matter? - a study in childhood hemiplegia. Dev Med Child Neurol. 1996; 38(2):156-65. DOI: 10.1111/j.1469-8749.1996.tb12087.x. View

16.

Goodman R, Graham P . Psychiatric problems in children with hemiplegia: cross sectional epidemiological survey. BMJ. 1996; 312(7038):1065-9. PMC: 2350882. DOI: 10.1136/bmj.312.7038.1065. View

17.

Nadel S, Newport M, Booy R, Levin M . Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis. 1996; 174(4):878-80. DOI: 10.1093/infdis/174.4.878. View

18.

Goldschneider I, Gotschlich E, Artenstein M . Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969; 129(6):1327-48. PMC: 2138665. DOI: 10.1084/jem.129.6.1327. View

19.

Peltola H, Makela H, Kayhty H, Jousimies H, Herva E, HALLSTROM K . Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med. 1977; 297(13):686-91. DOI: 10.1056/NEJM197709292971302. View

20.

LEPOW M, Goldschneider I, Gold R, Randolph M, Gotschlich E . Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics. 1977; 60(5):673-80. View